<div id="readability-page-1"><p><span>CareDx (NASDAQ:CDNA - Get Free Report)</span> was downgraded by investment analysts at Wall Street Zen from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research report issued on Saturday.</p><p>A number of other equities research analysts also recently weighed in on CDNA. BTIG Research lifted their price target on shares of CareDx from $22.00 to $25.00 and gave the company a &#34;buy&#34; rating in a research report on Thursday, November 6th. Weiss Ratings  reissued a &#34;hold (c-)&#34; rating on shares of CareDx in a research note on Monday, December 29th. Craig Hallum cut CareDx from a &#34;buy&#34; rating to a &#34;hold&#34; rating and set a $26.00 price target for the company. in a research note on Tuesday, January 6th. Zacks Research raised shares of CareDx from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a research report on Tuesday, November 18th. Finally, Wells Fargo &amp; Company increased their target price on shares of CareDx from $14.00 to $18.00 and gave the stock an &#34;equal weight&#34; rating in a research note on Monday, December 15th. Three investment analysts have rated the stock with a Buy rating and six have issued  a Hold rating to the company. Based on data from MarketBeat, the company  has a consensus rating of &#34;Hold&#34; and an average price target of $26.67.</p><p><b>View Our Latest Analysis on CDNA</b></p><h2>CareDx Stock Up 6.1%</h2><p>NASDAQ:CDNA opened at $19.47 on Friday. The firm has a market capitalization of $1.00 billion, a P/E ratio of 16.36 and a beta of 2.51. CareDx has a 12-month low of $10.96 and a 12-month high of $25.55. The stock's fifty day simple moving average is $19.56 and its 200-day simple moving average is $16.11. </p><p>CareDx (NASDAQ:CDNA - Get Free Report) last announced its quarterly earnings results on Tuesday, November 4th. The company reported $0.28 earnings per share for the quarter, beating analysts' consensus estimates of $0.13 by $0.15. CareDx had a net margin of 19.65% and a return on equity of 20.15%. The business had revenue of $100.06 million for the quarter, compared to the consensus estimate of $95.25 million. During the same period last year, the company posted ($0.14) EPS. CareDx's revenue for the quarter was up 20.7% on a year-over-year basis.  As a group, equities research analysts expect that  CareDx will post -0.9 earnings per share for the current year. </p><h2>Insider Buying and Selling at CareDx</h2><p>In related news, CEO John Walter Hanna, Jr. sold 19,280 shares of CareDx stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $21.16, for a total value of $407,964.80. Following the completion of the sale, the chief executive officer owned 597,405 shares of the company's stock, valued at approximately $12,641,089.80. This trade represents a 3.13% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In the last ninety days, insiders sold 29,636 shares of company stock worth $625,949. 4.40% of the stock is currently owned by corporate insiders. </p><h2>Institutional Trading of CareDx</h2><p>A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in shares of  CareDx in the second quarter worth $352,000.  Hood River Capital Management LLC increased its stake in  CareDx by 11.5% in the 2nd quarter. Hood River Capital Management LLC now owns 1,765,981 shares of the company's stock worth $34,507,000 after purchasing an additional 182,025 shares during the period.  Envestnet Asset Management Inc. increased its position in shares of  CareDx by 17.7% in the second quarter. Envestnet Asset Management Inc. now owns 22,489 shares of the company's stock valued at $439,000 after acquiring an additional 3,389 shares during the period.  Geode Capital Management LLC grew its position in shares of  CareDx by 3.4% in the 2nd quarter. Geode Capital Management LLC now owns 1,323,497 shares of the company's stock worth $25,864,000 after buying an additional 43,074 shares during the last quarter.  Finally, Zweig DiMenna Associates LLC purchased a new stake in shares of  CareDx in the 2nd quarter worth about $4,428,000. </p><h2>About CareDx</h2> (Get Free Report)<p>CareDx, Inc <span>NASDAQ: CDNA<span></span></span> is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey.  </p><p>The company's core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than CareDx</li><li>NEW LAW: Congress Approves Setup For Digital Dollar?</li><li>The day the gold market broke</li><li>What a Former CIA Agent Knows About the Coming Collapse</li><li>Your Bank Account Is No Longer Safe</li><li>He just nailed another gold prediction …</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0ROQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0ROQQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in CareDx Right Now?</h2><p>Before you consider CareDx, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CareDx wasn't on the list.</p><p>While CareDx currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Wall Street Zen downgraded CareDx (NASDAQ:CDNA) from a "buy" to a "hold" rating. Other analysts have mixed views, with BTIG Research raising the price target to $25 and maintaining a "buy" rating, while Weiss Ratings and Craig Hallum issued "hold" ratings. CareDx reported a quarterly EPS of $0.28, exceeding estimates, with a revenue increase of 20.7% year-over-year. The stock opened at $19.47, with a market cap of $1 billion. Insider trading activity includes CEO selling shares, and institutional investors have adjusted their positions in the stock.</p>

Market Beat

iShares Genomics Immunology and Healthcare ETF

Ark Genomic Revolution ETF

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

iShares US Medical Devices

iShares US Healthcare Providers

Health Care Select Sector SPDR

Caredex

VanEck Biotech ETF

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

iShares Biotechnology ETF

CareDx (NASDAQ:CDNA) Cut to "Hold" at Wall Street Zen